GlassScriptPhysician profile
Aditi More
NPI 1407416506
$4,107.90
in general payments reported to CMS, 2019-2025
29 companies · $552 in 2025
The $552 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $401 · 2023: $1,480 · 2024: $1,675 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671 · Education: $36.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,670.55 |
| Education | $36.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,078.03 | 2022-2025 | |
| Novo Nordisk INC | $555.06 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $412.89 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $365.61 | 2023-2024 | |
| Lilly USA, LLC | $273.33 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $183.76 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $135.79 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Eisai INC. | $115.33 | 2024 | |
| Axsome Therapeutics, INC. | $94.40 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.00 | 2022-2023 | Xifaxan |
| Exact Sciences Corporation | $90.46 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $90.05 | 2024-2025 | Repatha, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $80.75 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $57.86 | 2022-2024 | Eliquis |
| Amarin Pharma, INC. | $55.80 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.14 | 2023-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $51.63 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $47.53 | 2023 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.37 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Biohaven Pharmaceutical Holding Company LTD. | $32.48 | 2022 | |
| Insightec,INC | $29.56 | 2024 | Exablate |
| Vanda Pharmaceuticals INC. | $28.56 | 2025 | Hetlioz, Fanapt |
| Ultragenyx Pharmaceutical INC. | $25.02 | 2022 | |
| Merck Sharp & Dohme LLC | $24.38 | 2023 | Verquvo, Belsomra |
| Dexcom, INC. | $22.89 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $22.07 | 2024 | Korlym |
| Irhythm Technologies, INC. | $21.53 | 2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $17.89 | 2023 | Xarelto |
| Azurity Pharmaceuticals, INC. | $17.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditi More listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.